Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline.

@article{LaPlante2004ClinicalGS,
  title={Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline.},
  author={Kerry L LaPlante and Michael Joseph Rybak},
  journal={Diagnostic microbiology and infectious disease},
  year={2004},
  volume={50 2},
  pages={125-30}
}
We examined the activity of arbekacin, daptomycin, tigecycline, and vancomycin against various Staphylococci isolates with glycopeptide-intermediate (n = 25) and heterogeneous susceptibilities (n = 22) (GISS and hGISS). The minimum inhibitory concentrations (MIC) of each antimicrobial was evaluated in time-kill experiments by using 4 randomly selected GISS isolates tested at 2 and 4 times their respective MIC. The MIC(90) microg/mL ranges for arbekacin, daptomycin, tigecycline, and vancomycin… CONTINUE READING